Pacritinib
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 215 publications
Current treatments, practical management, and emerging investigational therapies for myelofibrosis.
Journal: Expert review of hematology
Published: December 14, 2025
Pacritinib in patients with myelodysplastic/myeloproliferative neoplasms.
Journal: Leukemia & lymphoma
Published: November 26, 2025
Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?
Journal: Future oncology (London, England)
Published: November 04, 2025
Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.
Journal: American journal of hematology
Published: October 23, 2025
Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases.
Journal: Hospital practice (1995)
Published: October 17, 2025
Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases.
Journal: Hospital practice (1995)
Published: October 17, 2025
Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
Journal: Se pu = Chinese journal of chromatography
Published: September 24, 2025
Development and Validation of a Simultaneous Quantification Method for 12 Targeted Therapies and 3 Active Metabolites in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: An Application to Therapeutic Drug Monitoring in Patients With Hematological Malignancies.
Journal: Therapeutic drug monitoring
Published: September 15, 2025
Inhibition of Interleukin-1 Receptor-Associated Kinase-1 by Pacritinib Is a Therapeutic Strategy to Overcome Melanoma Resistance.
Journal: Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
Published: September 08, 2025
Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs.
Journal: Journal of medicinal chemistry
Published: August 06, 2025
A new era in the treatment of myeloproliferative neoplasms
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 06, 2025
Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase.
Journal: Clinical and translational science
Published: August 05, 2025
Last Updated: 02/24/2026